WHAT DOES ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC) MEAN?

In Phase C, participants will acquire ABBV-744 and oral navitoclax. In Segment D, members will acquire ABBV-744 and ruxolitinib. Participants will obtain treatment until disorder progression or even the members are unable to tolerate the study drugs.Celastrol was determined for a Myb inhibitor that suppressed C/EBPβ activity and repressed AML cell